Costs in general practice

BMJ

Volumn 313, Issue 7065, 1996, Pages 1143-1144

  Robertson, Michael ^a  

^a Marcham Road Family Health Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN;

COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; GENERAL PRACTICE; HUMAN; HYPERCHOLESTEROLEMIA; NOTE; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG COSTS; FAMILY PRACTICE; HUMANS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; SCOTLAND;

EID: 0030566322     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.313.7065.1143b     Document Type: Letter

References (4)

1. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–8 (8 June.)
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7.
3. Scandinavan Simvastain Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383–9.
4. Office of Population Censuses and Surveys. Health survey of England. Information on distribution of cholesterol levels in the British population. London: OPCS, 1991.